AbClon's earnings have been declining at an average annual rate of -16.8%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 3.6% per year.
How AbClon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A174900 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
4,736
-15,015
3,847
12,059
31 Dec 25
4,714
-18,104
4,025
14,431
30 Sep 25
3,801
-16,230
3,580
12,538
30 Jun 25
3,033
-16,134
3,362
12,916
31 Mar 25
2,315
-16,629
3,206
13,068
31 Dec 24
2,340
-16,302
2,673
13,394
30 Sep 24
2,193
-18,173
2,678
14,026
30 Jun 24
2,072
-18,976
2,636
14,711
31 Mar 24
2,437
-16,525
2,530
13,723
31 Dec 23
2,877
-12,904
2,454
10,734
30 Sep 23
3,005
-9,424
1,957
9,324
30 Jun 23
3,267
-7,782
2,273
7,588
31 Mar 23
3,468
-8,728
2,102
8,280
31 Dec 22
3,404
-9,244
2,023
8,693
30 Sep 22
3,170
-9,759
2,486
8,806
30 Jun 22
2,912
-8,964
1,946
8,342
31 Mar 22
3,262
-11,027
1,911
10,333
31 Dec 21
3,018
-10,238
1,831
9,626
30 Sep 21
3,232
-9,905
1,706
9,236
30 Jun 21
3,260
-9,178
1,669
8,599
31 Mar 21
2,482
-6,731
1,617
5,691
31 Dec 20
2,771
-6,445
1,557
5,859
30 Sep 20
3,196
-5,538
1,416
5,565
30 Jun 20
3,005
-5,132
1,595
5,093
31 Mar 20
3,258
-4,534
1,801
3,879
31 Dec 19
14,375
2,567
5,068
2,816
30 Sep 19
14,758
4,039
5,339
2,507
30 Jun 19
14,883
3,898
5,163
2,714
31 Mar 19
14,753
4,802
4,926
2,655
31 Dec 18
3,921
-843
1,605
2,368
30 Sep 18
3,031
-2,047
1,471
2,022
30 Jun 18
2,908
-1,850
1,458
1,789
31 Mar 18
3,094
-1,578
1,455
1,707
31 Dec 17
3,532
-1,483
1,715
1,717
30 Sep 17
3,421
-1,644
1,632
1,831
30 Jun 17
3,497
-1,617
1,597
1,860
31 Mar 17
4,193
-951
1,542
1,982
31 Dec 16
3,120
-1,597
1,275
1,992
30 Sep 16
3,173
-1,949
248
3,329
30 Jun 16
3,047
-1,794
819
2,879
31 Mar 16
1,994
-2,767
1,343
2,290
31 Dec 15
1,948
-9,842
1,607
1,852
Quality Earnings: A174900 is currently unprofitable.
Growing Profit Margin: A174900 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A174900 is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare A174900's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A174900 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.6%).
Return on Equity
High ROE: A174900 has a negative Return on Equity (-25.24%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/16 09:48
End of Day Share Price
2026/06/16 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbClon Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.